SYNJARDY: payments to doctors
Payments that named SYNJARDY as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $1.7M
- Providers
- 25,074
- Transactions
- 97,704
- Average per transaction
- $17
The per-transaction average — $17 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 25,074 providers the average total is $67, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Boehringer Ingelheim | $1,611,380 | 95.8% |
| Lilly USA, LLC | $64,252 | 3.8% |
| Boehringer Ingelheim South Africa (pty) Ltd | $4,350 | 0.3% |
| Boehringer Ingelheim India Pvt. Ltd. | $2,800 | 0.2% |